PubMed · 1992 · 721 citations · 32 references
MedicineCancer BiologyOncologyDrug DiscoveryMedical OncologyMolecular OncologyCancer BiotechnologyCancer Precision MedicineDrug DevelopmentMalignant NeoplasmsOncology PharmacologyTumor BiologyCancer BioinformaticsTranslational Oncology Drug Development
The discovery and development of novel therapeutic products for the treatment of malignancy is vitally important to those physicians responsible for the management of cancer patients. A description of the ongoing efforts at the National Cancer Institute (NCI) is intended to provide insight into those complex processes necessary to accomplish this mission. An update on the NCI's revised cancer screen is accompanied by a brief summary of those new agents scheduled to be entered into clinical investigation in the near future. The tremendous potential advantages and challenges associated with the use of a molecular approach to cancer drug design are discussed. Despite the differences of opinion that may exist regarding the optimal strategies for accomplishing the mission, there is no disagreement regarding the importance of the effort to find effective new therapies for cancer patients.
32
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Philip Skehan, Ritsa Storeng, Dominic A. Scudiero et al. · JNCI Journal of the National Cancer Institute · 1990 · 9.8K citations
Medicine, Oncology, Pharmacology +10
Tyrosine Kinase Activity and Transformation Potency of <i>bcr-abl</i> Oncogene Products
T G Lugo, Ann Marie Pendergast, Alexander J. Muller et al. · Science · 1990 · 1.3K citations
Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
Donald E. Ingber, Takeshi Fujita, SHOJI KISHIMOTO et al. · Nature · 1990 · 1.3K citations
Medicine, Oncology, Pharmacology +14
Kenneth D. Paull, Robert H. Shoemaker, Louis Hodes et al. · JNCI Journal of the National Cancer Institute · 1989 · 969 citations
Medicine, Biostatistics, Oncology +16